Attached files
file | filename |
---|---|
10-K - ARCT 10-K 20201231 - Arcturus Therapeutics Holdings Inc. | arct-10k_20201231.htm |
EX-32.3 - EX-32.3 - Arcturus Therapeutics Holdings Inc. | arct-ex323_15.htm |
EX-32.1 - EX-32.1 - Arcturus Therapeutics Holdings Inc. | arct-ex321_6.htm |
EX-31.3 - EX-31.3 - Arcturus Therapeutics Holdings Inc. | arct-ex313_8.htm |
EX-31.2 - EX-31.2 - Arcturus Therapeutics Holdings Inc. | arct-ex312_10.htm |
EX-31.1 - EX-31.1 - Arcturus Therapeutics Holdings Inc. | arct-ex311_13.htm |
EX-23.1 - EX-23.1 - Arcturus Therapeutics Holdings Inc. | arct-ex231_12.htm |
EX-10.30 - EX-10.30 - Arcturus Therapeutics Holdings Inc. | arct-ex1030_393.htm |
EX-10.29 - EX-10.29 - Arcturus Therapeutics Holdings Inc. | arct-ex1029_392.htm |
EX-4.1 - EX-4.1 - Arcturus Therapeutics Holdings Inc. | arct-ex41_391.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
In connection with the Annual Report of Arcturus Therapeutics Holdings Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2020 (the “Report”), I, Andrew Sassine, Chief Financial Officer and Director of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 1, 2021 |
By: |
|
/s/ Andrew Sassine |
|
|
|
Andrew Sassine |
|
|
|
Director and Chief Financial Officer (principal financial officer) |